Homing potential of the antigen specific B cell and antibody mediated immune response after vaccination Spesifisten B solujen kotiutumispotentiaali ja vasta-aine vaste rokotetuilla

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 21 Apr 2012

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cholera vaccine inactivated (Primary) ; Influenza A virus vaccine-H1N1 (Primary) ; Influenza virus vaccine (Primary) ; Pneumococcal 7-valent CRM197 vaccine conjugate (Primary) ; Typhoid vaccine Vi-polysaccharide (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate; Pneumococcal vaccine; Typhoid-vaccine-Ty21a
Indications Cholera; Influenza A virus H1N1 subtype; Influenza virus infections; Pneumococcal infections; Typhoid
Focus Pharmacodynamics

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com